Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SELL | P14151 | 2/20 | 0.37 |
| ▸ | SELP | P16109 | 2/20 | 0.37 |
| ▸ | SELE | P16581 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19465745 | 1.00 | ALDH1A1 (0.51) | ALDH1A1SMYD3JAK1PLGPLAT | |
| SCHEMBL10179186 | 0.91 | TSHR (0.43) | ALDH1A1SMYD3JAK1PLGPLAT | |
| SCHEMBL1679362 | 0.83 | — | — | |
| SCHEMBL28728308 | 0.81 | TP53 (0.46) | ALDH1A1SMYD3JAK1CA12CA7 | |
| SCHEMBL19704913 | 0.81 | TP53 (0.46) | ALDH1A1SMYD3JAK1CA12CA7 | |
| SCHEMBL3171363 | 0.80 | ALDH1A1 (0.54) | ALDH1A1PLGPLATLMNACA12 | |
| SCHEMBL15803197 | 0.80 | ALDH1A1 (0.54) | ALDH1A1PLGPLATLMNACA12 | |
| SCHEMBL17872669 | 0.78 | SMYD3 (0.41) | ALDH1A1SMYD3JAK1CA12CA7 | |
| SCHEMBL2879823 | 0.78 | ALDH1A1 (0.46) | ALDH1A1PLGPLATLMNACA12 | |
| SCHEMBL90846 | 0.76 | ALDH1A1 (0.50) | ALDH1A1PLGPLATLMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| CN-109743875-B | Inhibitors of the MENIN-MLL interaction | 生命医药有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3805215-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210053974-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3468966-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2019-05-16 | — | — | US | disclosed |
| EP-3468966-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017214367-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ALDH1A1 4369/4885SMYD3 120/4885JAK1 4005/4885 |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ALDH1A1 4369/4885SMYD3 120/4885JAK1 4005/4885 |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | ALDH1A1 4369/4885SMYD3 120/4885JAK1 4005/4885 |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | ALDH1A1 4369/4885SMYD3 120/4885JAK1 4005/4885 |
| US-20210053974-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ALDH1A1 4369/4885SMYD3 120/4885JAK1 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.